The team were very productive at ISPOR this year, where Fatima Chunara gave a fantastic podium presentation to an audience of over 300 people on the topic: “Is market access for oncology treatments easier in England than for non-oncology treatments? An analysis of NICE single technology appraisals from 2017-2019”. The details of the presentation can be found here.
We also successfully presented 4 posters on various subjects:
- Are patient access schemes and commercial access agreements essential for NICE to recommend access? A comparison of oncology and non-oncology appraisals
- Pricing and market access launch excellence: what are the key challenges facing companies today?
- Are acute therapies and curative drugs more affordable than chronic treatments in rare diseases? An analysis of the top 20 most expensive drugs in the US
- Was the evidence base for Yescarta and Kymriah sufficient to justify their cost and secure patient access across 5 markets?
Our new exhibition stand generated plenty of attention during the three days with lots of people taking photo’s and asking questions around how Remap Consulting can support their market access challenges – a hot topic of conversation was how we can help gain the optimum price for your product at launch. If you would like to know more, please contact us.
We are very much looking forward to next year’s ISPOR conference in Milan – we hope to see you there!